CMO

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, Checkpoint, and Sonder and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, April 17, 2024
FDA, Radiation, Prospectus, MCI, CMO, Sonder, Crohn's disease, News, Food, Annual report, Complaint, Radar, Security (finance), Rett syndrome, Biologics license application, Form, P.C, IPO, Patient, Defendant, Acquisition, Psoriasis, CKPT, Inflammation, BLA, Register, Bank statement, CRL, Clinical trial, File, Pharmaceutical industry

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Key Points: 
  • The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
  • On this news, Checkpoint's stock price fell $1.49 per share, or 44.88%, to close at $1.83 per share on December 18, 2023.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CKPT

Retrieved on: 
Tuesday, April 16, 2024
FDA, Radiation, Action Replay, CMO, LLP, Person, Prior, News, Food, Complaint, Pomerantz, Biologics license application, District court, Patient, Court, Ext, Acquisition, CKPT, BLA, Checkpoint

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) and certain officers.

Key Points: 
  • NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Retailers With the Highest Identification Rates See 53% Higher Repeat Purchase Rates Finds New Report from Bluecore

Retrieved on: 
Tuesday, April 16, 2024
Growth, Health, Philosophy, CMO, DTC, ID, Jewellery, Calendar, Acquisition, Luxury, Risk

While every vertical has unique trends, Bluecore finds that across the board, retailers focused on the metrics and best practices that drive customer movement have higher performance across the customer lifecycle.

Key Points: 
  • While every vertical has unique trends, Bluecore finds that across the board, retailers focused on the metrics and best practices that drive customer movement have higher performance across the customer lifecycle.
  • Retailers with average ID rates above 40% saw repeat purchase rates that were 53% higher than the average.
  • At the same time, retailers with ID rates below 10% saw repeat purchase rates that were 33% lower than the average.
  • Our philosophy and practice of ‘customer movement’ is founded on customer centricity, which the data shows drives higher purchase rates, retention rates and revenue,” said Jason Grunberg, CMO at Bluecore.

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Retrieved on: 
Tuesday, April 16, 2024
LC-MS, Therapy, CMO, Patient, PDE4, Autoimmunity, UC, Fine chemical

Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.

Key Points: 
  • These findings demonstrated that PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with UC.
  • The enzymatic activity in stool samples was assessed using LC-MS analysis with all stool samples meeting the target conversion rate within a 24-hour period.
  • The assessment showed PALI-2108 was converted into its active PDE4 inhibitor form at a mean rate of 90.1% with conversion steadily increasing over time.
  • "The results from this study underscore our confidence in PALI-2108 as a targeted treatment for moderate-to-severe UC," said Dr. Mitch Jones, CMO at Palisade Bio.

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

Retrieved on: 
Tuesday, April 16, 2024
Retina, AMD, FDA, CMO, CDO, Diabetic retinopathy, Doctor of Philosophy, OD, Appointment, Patient, MPH, CSO, Health, Diabetes, Clinical trial, Quality of life, Retinal, Nursing

BEDFORD, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has strengthened its clinical development organization with the appointment of Nadia K. Waheed, MD, MPH, as Chief Medical Officer (CMO); Peter K. Kaiser, MD as Chief Development Officer (CDO); Andrea Gibson, Ph.D., as Vice President, Medical Collaborations; and Namrata Saroj, OD, as Development Strategy Consultant. Dr. Waheed’s appointment will be effective as of May 20, 2024. Jeffrey S. Heier, MD, will continue in his role as Chief Scientific Officer (CSO).

Key Points: 
  • “I am thrilled to announce the enrichment of Ocular’s clinical development organization with the appointment of four recognized retinal disease professionals.
  • Having a strong team of retinal leaders with experience across all aspects of clinical development is essential to Ocular’s transformation to becoming a leading retina company,” said
    Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer of Ocular Therapeutix.
  • In addition, I believe our strengthened clinical team also puts Ocular in an excellent position to accelerate expansion into retinal indications beyond wet AMD, including diabetic retinopathy.”
    Dr. Waheed said, “I am honored to be part of the Ocular Therapeutix team.
  • I joined Ocular because I believed that AXPAXLI could be a ‘game-changer’ in the care of retinal disease.

CKPT Class Action Alert: Robbins LLP Reminds Stockholders of Checkpoint Therapeutics, Inc. Class Action

Retrieved on: 
Monday, April 15, 2024
FDA, Radiation, CMO, LLP, News, Patient, Acquisition, CKPT, BLA, Checkpoint, SAN, Person, Pharmaceutical industry

SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) securities between March 10, 2021 and December 15, 2023.

Key Points: 
  • SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) securities between March 10, 2021 and December 15, 2023.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

Web 3.0 Open - Meta Era Reunion in Dubai Unveils Stellar Line-Up and Official Agenda

Retrieved on: 
Monday, April 15, 2024
Cloud, Decentralized finance, CMO, News, Speech, Privacy, Entrepreneurship, Attention, RABI, WSPN, Partner, QR, Golf, EMC, Cryptocurrency and crime, Business development, Deep diving, KUN, SPHEREx, Cryptocurrency

Hongkong, China, April 15, 2024 (GLOBE NEWSWIRE) -- Meta Era, a leading media outlet based in Hong Kong, is pleased to announce the "Web 3.0 Open - Meta Era Reunion in Dubai," an exclusive high-end industry networking event set to take place at MyGolf Dubai on April 20, 2024, during the TOKEN2049 Dubai conference.

Key Points: 
  • Hongkong, China, April 15, 2024 (GLOBE NEWSWIRE) -- Meta Era, a leading media outlet based in Hong Kong, is pleased to announce the "Web 3.0 Open - Meta Era Reunion in Dubai," an exclusive high-end industry networking event set to take place at MyGolf Dubai on April 20, 2024, during the TOKEN2049 Dubai conference.
  • Gathering under a shared passion for golf, participants will exchange insights on the hot trends in the Web 3.0 industry and share their respective investment experiences.
  • Mr. Eric Bai, CEO of Meta Era, will deliver the opening address.
  • Raymond Yuan, Founder of WSPN, will discuss how Web3 X AI fosters new opportunities for democratization in his keynote speech.

WalkMe Cements Category Leadership with Continued AI Innovation, Industry Recognition, and Financial Growth

Retrieved on: 
Monday, April 15, 2024
Doctor of Philosophy, Public sector, Soda, WalkMe, CMO, ROI, Investment, Certification, AI, Jelly shoes, Customer success, DAP, Workplace, Research, Digital adoption platform, Realize, Digital, FedRAMP, TechTarget, Patent, Category, IDC, TAM, AWS, SAN, Accenture, Cryptocurrency

Achievements include a bold array of AI-centric product innovations and patents, analyst and industry recognition, superior customer service reviews, category-defining thought leadership, and continued financial growth.

Key Points: 
  • Achievements include a bold array of AI-centric product innovations and patents, analyst and industry recognition, superior customer service reviews, category-defining thought leadership, and continued financial growth.
  • Its platform drives the proper adoption and value realization of technology investments, making the company an essential partner in organizations’ AI strategies.
  • WalkMe’s financial growth has marked a transformative year, as it emerged a profitable company with revamped processes and continued operational improvements in 2023.
  • Thought Leadership & Category Research: As the clear category leader, WalkMe continually invests in research and thought leadership.

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Monday, April 15, 2024
FDA, Radiation, CMO, News, Complaint, Patient, Court, CKPT, BLA, CRL, Person

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

Key Points: 
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Checkpoint you have until June 4, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, April 13, 2024
FDA, Radiation, Prospectus, MCI, CMO, Crohn's disease, News, Food, Complaint, Radar, Security (finance), Rett syndrome, Biologics license application, Form, P.C, IPO, Patient, Defendant, Acquisition, Psoriasis, CKPT, Inflammation, BLA, Register, CRL, Clinical trial, File, Pharmaceutical industry

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Key Points: 
  • The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party [CMO] as approvability issues to address in a resubmission."
  • On this news, Checkpoint's stock price fell $1.49 per share, or 44.88%, to close at $1.83 per share on December 18, 2023.